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Background: Papillary renal cell carcinoma (RCC) represents a rare tumor, which is divided, based on histological
criteria, into two subtypes. In contrast to type I papillary RCC type II papillary RCC shows a worse prognosis. So far,
reliable immunohistochemical markers for the distinction of these subtypes are not available.
Methods: In the present study the expression of N(neural)-, E(epithelial)-, P(placental)-, und KSP(kidney specific)-
cadherin was examined in 22 papillary RCC of histological type I and 18 papillary RCC of histological type II
(n = 40).
Results: All papillary RCC type II displayed a membranous expression for N-cadherin, whereas type I did not show
any membranous positivity for N-cadherin. E-cadherin exhibited a stronger, but not significant, membranous as well
as cytoplasmic expression in type II than in type I papillary RCC. A diagnostic relevant expression of P- and
KSP-cadherin could not be demonstrated in both tumor entities.
Conclusion: Thus N-cadherin represents the first immunhistochemical marker for a clear cut differentiation
between papillary RCC type I and type II and could be a target for therapy and diagnostic in the future.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2011556982761733
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Renal cell carcinoma (RCC) represents a rather rare
cancer with about 71,000 newly diagnosed cases per year
in Europe. Approximately 31,000 of these patients die
because of RCC [1]. The RCCs are devided in different
histological subtypes, of which the group of papillary
RCC compromise less than 10% of all RCC [2]. Based on
histological criterias type I and type II papillary RCCs
can be distinguished: Type I papillary RCCs show papillae
covered by a single layer of cuboidal cells with a small
cytoplasmic rim; furthermore, type I tumors are often
infiltrated by numerous foamy macrophages. Type II
tumors also form papillae covered by a monolayer of
tumor cells; in contrast to type I papillary RCC these* Correspondence: clbehnes@med.uni-goettingen.de
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reproduction in any medium, provided the ortumor cells display higher nuclear polymorphism with
pseudostratification and abundant mostly eosinophilic
cytoplasm; foamy macrophages, however, are rarely seen
in type II papillary RCCs [3]. As typical chromosomal
changes the loss of Y chromosome or significantly higher
numbers of gains of 7p, 17p, and 17q were demonstrated
in papillary RCCs [4,5]. Klatte et al. [6] could show a loss
of 1p, loss of 3p, and a gain of 5q exclusively in type II
papillary RCC by cytogenetic analyses. The subdivision of
papillary RCC into two subtypes is important, because
type II papillary RCC shows a shorter survival rate
because of its higher grade of malignancy and progressed
stage at the time of diagnosis [7-9].
Cadherins are transmembrane glycoproteins and play
a role in Ca2+-dependent cell-cell contacts especially in
adherent junctions and in the development of different
organs [10,11]. They are also involved in genesis of
tumors and act as metastasis suppressing proteins [12].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cancers and is associated with increased metastatic
potential. This could be shown in breast cancer for the
extensively studied E-cadherin [13]. Current investiga-
tions showed a worse prognosis for tumors with a non
tissue specific cadherin expression [14]. In the present
study the expression of N-, E-, P-, and KSP-cadherin in
both subtypes of papillary RCC were examined in order
to find diagnostically relevant differences.
Methods
Tissue samples
Tumor-tissue of radical or partial nephrectomy speci-
mens from 40 patients suffering from papillary RCC
were included in this study and analysed for the expres-
sion of N-, E-, P- und KSP-cadherin. All tumors were
classified in papillary RCC subtypes and staged on the
basis of WHO classification [15]. Clinical and histo-
pathological data are summarized in Table 1.
Immunohistochemistry
Primary immunohistochemical reactions for the analysed
cadherins were performed on paraffin-embedded sections
of papillary RCC as listed in Table 2. Thereafter sections
were incubated with a horseradish peroxidase (HRP)-
conjugated polymer consisting of antibodies to rabbit
and mouse immunoglobulins (EnVision/HRP, Dako,
Hamburg, Germany). Specific binding was visualized
with 3,3_- diaminobenzidine (DAB; Dako). All samples were
counterstained with Meyer’s haematoxylin, mounted in
Super Mount Medium, and analysed by light microscopy.
All sections were evaluated by two independent inves-
tigators for membranous and cytoplasmic staining using
the immunoreactive staining score (IRS). To establish
the IRS, the percentage of positive-stained cells was
evaluated first using a 0–5 scoring system: 0% of positive
cells resulted in a score of 0, less than 1% in a score of 1,Table 1 Clinical and pathological data of analysed cases
papRCC subtype I papRCC subtype II
n (men/women) 22 (18/4) 18 (9/9)
mean age (years) 69,72 71,38
,7 T1 (a/b) 13(7/6) 4(3/1)
nT2 7 1







nN2 0/22 5/181–10% in a score of 2, 10–33% in a score of 3, 33–66%
in a score of 4 and 66–100% in a score of 5. Staining
intensity was evaluated by a gradual scale (0, negative; 1,
weak; 2, intermediate; 3, strong). For the final score the
scores of intensity and of positive tumor cells were
added and the mean value was calculated.
Statistical analysis
For statistical analyses the IRS was compared between
papRCC subtypes using the Wilcoxon test (GraphPad
Software, SanDiego, CA, USA). A P value of < 0.05 was
considered to show a significant difference. All data are
presented as mean ± standard error of the mean (SEM).
Results
Immunohistochemical examinations revealed a mem-
branous positivity for N-cadherin in all papillary RCC
type II (IRS 6.28 ± 1.57), whereas type I did not show
any membranous positivity for N-cadherin (IRS 0). In
contrast to the membranous N-cadherin expression the
cytoplasmic expression of N-cadherin showed a higher
score in papillary RCC type I (IRS 5.68 ± 1.76) than in
type II (IRS 2.5 ± 2.0); cytoplasmic N-cadherin was
particularly detectable in the apical and basolateral parts
of the tumorcells. The comparison between both subtypes
of papillary RCC for cytoplasmic N-cadherin showed a
significant difference (P < 0.0032) (Figure 1A-D and
Figure 2).
The E-cadherin staining showed in the majority of papil-
lary RCC type II a weak membranous (IRS 1.83 ± 2.72) as
well as cytoplasmic expression (IRS 1.89 ± 2.49). In papil-
lary RCC type I a decreased expression of membranous
(IRS 1.28 ± 1.95) and an approximately similar cytoplasmic
E-cadherin (IRS 1.81 ± 1.94) could be determined. A
statistical comparison showed no significant difference for
membranous as well as cytoplasmic E-cadherin expression
in both subtypes of papillary RCC (p = n. s.) (Figure 3A, D
and Figure 2).
A weak membranous expression of P-cadherin could
be demonstrated for type I (IRS 0.54 ± 1.79) and type II
(IRS 0.83 ± 1.38) papillary RCC without significant dif-
ferences (p = n .s.). The investigation of cytoplasmic
P-cadherin demonstrated an almost equal expression
in type II and type I papillary RCC (IRS 2.27 ± 2.86 vs.
2.22 ± 1.97) (Figure 3B, E and Figure 2).
A membranous KSP-cadherin expression could only be
demonstrated in some cases of papillary RCC type II (IRS
0.83 ± 1.65) and papillary RCC type I (IRS 0.73 ± 1.61).
Cytoplasmic KSP-cadherin was only weakly expressed in
papillary RCC type II (IRS 2.17 ± 2.71) as well as type I
(IRS 2.36 ± 2.44). The statistical analysis showed no
significant differences for membranous and cytoplasmic
KSP-cadherin expression in both subtypes of papillary
RCC (p = n. s.) (Figure 3C, F and Figure 2).
Table 2 Applied antibodies and conditions for primary immunohistochemical reaction
N-Cadherin E-Cadherin P-Cadherin KSP-Cadherin
Clone 6 G11 (mouse) NCH-38 (mouse) 56C1 (mouse) MRQ-33 (mouse)
Source Dako, Hamburg Dako, Hamburg Linaris, Dossenheim Zytomed Systems, Berlin
Germany Germany Germany Germany
Pretreatment citrate buffer citrate buffer citrate buffer citrate buffer
pH6.0 40 min pH6.0 40 min pH6.0 40 min pH6.0 40 min
Dilution and 1:50 30 min RT 1:50 30 min RT 1:100 30 min RT 1:50 30 min RT
Incubation
RT: room temperature.
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or tumor stage could not be observed.
Normal kidney tissue showed an irregular weak to
intermediate cytoplasmic expression of the investigated
cadherins in proximal and distal tubular. A membranous
expression of cadherins could not be observed at all.
Discussion
Papillary RCC represents a subtype of RCC with a typical
morphology and typical characteristic genetic aberrations
[3,6]. Several investigations could define a prognostic
relevant subdivision into type I and type II papillary RCC
[7-9]. This subdivision can so far only be done by mor-
phological criteria [16,17]. Several immunohistochemicalA
C
Figure 1 Immunohistochemistry of N-cadherin expression in papillary
abundant cytoplasm of the tumor cells (A, x20) displays a strong membran
single layer of cuboidal cells and a small cytoplasmic rim (C, x20) shows onmarkers were applied to find any useful differentiation
criteria between the two subtypes. Cytokeratin-7 could be
etablished as a helpful marker, because it is detectable in
more than 80% of type I tumors, whereas type II papillary
RCC in only 20% express cytokeratin-7 [3,18]. Perret et al.
could demonstrate a significant higher MUC-1 expression
in type I papillary RCC [19]. Zhou et al. [20] described that
E-cadherin could help to distinguish between type I and
type II of papillary RCC. Other typical antigens for renal
neoplasm such as CD10 were also investigated but did not
show any significant differences [21,22]. N-cadherin, pri-
marily described as A-CAM, was shown to be expressed by
normal renal epithelium [23,24]. Furthermore Markovic-
Lipovski et al. could show an expression of N-cadherin inB
D
RCC. Papillary RCC type II with high nuclear polymorphism and
ous expression of N-cadherin (B, x40). Papillary RCC type I with a




Figure 2 Histopathological evaluation of cadherin expression in both sybtypes of papillary RCC. N-cadherin showed a significant
difference in membranous and cytoplasmic expression between both subtypes of papillary RCC. A significant difference for E-, P- and KSP-
cadherin expression could not be demonstrated.
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RCC [25].
We investigated the expression of four different cadherins
in type I and type II papillary RCC. It could be demon-
strated that all investigated papillary RCC type II showed a
membranous expression of N-cadherin, whereas type I did
not show any membranous N-cadherin. In contrast, type I
papillary RCC showed a significant higher cytoplasmic
expression for N-cadherin compared to type II. Cadherins
are transmembrane glycoproteins, which act as cell-cell
contacts and in signal transduction. Only if the cadherins
are localized in the membrane, these functions can be
executed [26]. Therefore the observed cytoplasmic cadherin
expression must be accompanied by a loss function.N-cadherin is normally expressed in neuronal tissue
and plays a key role in organ development [27]. An
non tissue specific expression of N-cadherin as found
for papillary RCC type II could be shown to induce
cell migration, metastases, and invasion especially in
breast cancer [14]. This process is also known as
epithelial-mesenchymal transition (EMT) and it plays
a crucial role in embryonic development [28]. In
tumors this transition promotes the mobility and inva-
sive capacity of tumor cells and it is associated with a
progression of tumor disease [29,30]. In addition EMT
is connected with cancer stem cell-like features, which
include the development of resistances to chemother-
apy [31,32].
Figure 3 Immunohistochemistry of E-, P-, KSP- and cadherin expression in papillary RCC. Expression of E- (A / D), P- (B / E) and KSP-
cadherin (C / F) in papillary RCC type II (A, B, C x20) and type I (D, E, F x20). The expression patterns are not suitable for a clear cut differentiation
of both tumor subtypes (for details see results).
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behaviour of papillary RCC type II in comparison to type
I as previously described [7-9]. For different other tumors
it could also be shown that not only the non tissue specific
expression of N-cadherin but also the switch from different
cadherins to N-cadherin is associated with a worse progno-
sis [33,34]. In addition the activation of the PI-3 kinase /
Akt Pathway induced by N-cadherin could be demon-
strated as a survival mechanism for lung cancer [35].
Our data show a higher expression of E-cadherin in
papillary RCC type II. It is widely accepted that an
increased expression of E-cadherin in cancer is asso-
ciated with a better outcome and a decrease occurrence of
metastases [13]; in ovarian carcinoma lower E-cadherin
seems to influence the transition from normal ovarian
surface epithelium to ovarian cancer [36]. The investiga-
tion of KSP-cadherin showed only a weak membranous
and cytoplasmic expression in both subtypes of papillary
RCC. These findings for KSP-cadherin correlate with
those of other working groups [37]. P-cadherin expression
which plays an important role in ovarian cancer also incase of cadherin switch [38] did not show a prominent
expression in papillary RCC.
In conclusion, N–cadherin could be established as the
first immunohistological marker for a clear cut differen-
tiation between papillary RCC subtype I and II. Furthermore,
the data implicate that cadherins especially N-cadherin and
the involved pathway via p120 catenin, which is used by
most cadherins, could play a pivotal role for the therapy of
RCC as already shown for other neoplasias [39-41].
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